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Abstract 
Review on +X solely in myeloid malignancies, with 
data on clinics. 
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Identity 
Figure 1.  Fluorescence in situ hybridization with centromeric CEP X/Y probe (Abbott Molecular, Vysis, US) 
showing 3 copies of chromosome X (red signal) in metaphase and interphase cells. Partial karyotype showing an 
extra copy of chromosome X (inset). 
Clinics and pathology 
Disease 
Chronic myeloproliferative disorders and acute 
myeloid leukemia 
Epidemiology 
9 patients diagnosed with myeloid malignancies (6 
males and 3 females) aged 27 to 73 years (median 50 
years);  among them there 5 acute myeloid leukemia 
(AML) cases, not associated  with  a  particular 
leukemia  subtype:  1 acute monoblastic leukemia 
(AML-M5) (Akiyoshi et al., 1991), 1 acute 
myeloblastic leukemia with maturation  (AML-M2) 
(Wan et al., 2002), 1 acute myeloblastic leukemia 
with minimal differentiation  (AML-M0) (Dicker et 
al., 2007) and 2  cases  of  childhood  AML 
(Raimondi et al 1999). 4 patients had various 
disorders: 1 secondary myelodysplastic syndrome 
(MDS) developed after chemotherapy for Hodgkin's 
disease  (Pedersen-Bjergaard et al 1997), 1 chronic 
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neutrophilic leukemia  (Yamamoto et al., 2002), 1 
bilineage or biphenotypic leukemia  (Tsutsumi et al., 
2005) and 1 chronic myeloid leukemia  patient who 
developed trisomy 8 /trisomy X abnormalities in 
Philadelphia-negative cells during imatinib mesylate 
treatment (Kim et al., 2008) (Table 1). Extra 
chromosome X was also reported in 2 patients 
receiving high dose chemotherapy who developed 
blood cytopenias as well as subtle to mild dysplastic 
features after autologous stem cell transplantation, 
which were not classifiable as MDS (Martinez-
Climent et al., 2000)  
 
Table  1. Clinical and  karyotypic data of patients with myeloid malignancies and +X solely.
 
  Sex/Age Diagnosis Karyotype 
1 F Acute monoblastic leukemia 47,XX,+X 
2 M/27 
Refractory anemia 
previous chemotherapy for Hodgkin's disease 
47,XX,+X 
3 M Acute myeloid leukemia 47,XY,+X 
4 M Acute myeloid leukemia 47,XY,+X 
5 F/58 
Nonneoplastic hematologic disorder/lesion 
chemotherapy for adenocarcinoma  
47,XX,+X      transient  
6 F/43 
Nonneoplastic hematologic disorder/lesion 
chemotherapy for  adenocarcinoma 
47,XX,+X      transient  
7 M/73 Chronic neutrophilic leukemia 47,XY,+X       at progression 
8 F/44 Acute myeloblastic leukemia with maturation  47,XX,+X 
9 M/67 Bilineage or biphenotypic leukemia  47,XY,+X 
10 M Acute myeloblastic leukemia with minimal differentiation 55,XY,+X,+4,+5,+8,+10,+13,+14,+17,+18/47,XY,+X 
11 F/50 Chronic myeloid leukemia 
47,XX,+8  
47,XX,+X transient 
 Abbreviations: M, male; F, female.  
1. Akiyoshi et al, 1991; 2. Pedersen-Bjergaard et al.,  1997; 3. Raimondi et al., 1999; 4. Raimondi et al., 1999; 5. 
Martinez-Climent  et al., 2000; 6. Martinez-Climent et al., 2000; 7. Yamamoto et al., 2002; 8.  Wan et al., 2002; 
9. Tsutsumi et al., 2005; 10. Dicker et al., 2007; 11. Kim et  al., 2008. 
 
Prognosis 
Unknown, due to few number of patients and limited 
clinical data; the case with a secondary MDS, which 
developed 4 months after autologous stem cell 
transplantation for Hodgkin's lymphoma died 2 
months after the onset of MDS (Pedersen-Bjergaard 
et al.,1997). The 44-year-old woman with acute 
myeloblastic leukemia with maturation and 
abnormal eosinophils in the bone marrow developed 
diffuse alveolar damage and pulmonary hemorrhage 
while on induction chemotherapy and died 9 days 
after institution of chemetherapy (Wan et al., 2002). 
The 73-year-old man with chronic neutrophilic 
leukemia had normal karyotype at diagnosis, but 
after therapy with hydroxyurea for 7 months, the 
disease progressed to a blast crisis accompanied by 
appearance of an extra X chromosome, suggesting 
its role in the progression from chronic phase to the 
blast crisis of CNL (Yamamoto et al 2002). The 50-
years old female with chronic myeloid leukemia 
developed only transient trisomy X in Philadelphia-
negative cells during imatinib mesylate treatment 
(Kim et al., 2008). 
Genetics 
The observation of an extra chromosome X may 
indicate constitutional or acquired anomaly, 
therefore it should be carefully interpreted when an 
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extra X chromosome is the only abnormality or 
present in a form of chromosomal mosaicism in 
patients with hematologic malignancy. 
Result of the chromosomal 
anomaly 
Fusion protein 
Oncogenesis 
An extra X chromosome as a sole acquired 
abnormality has been reported in patients with 
several hematologic malignancies especially in 
childhood acute lymphoblastic leukemia  and 
lymphomas. While whole chromosome gains are 
frequent cytogenetic aberrations in myeloid 
malignancies, gain of X chromosome as the sole 
anomaly has been only occasionally observed. Its 
occurrence in both chronic and acute myeloid 
malignancies suggest involvement of multiple 
hematopoietic lineages. The presence of an 
additional copy of chromosome X might result in 
increased gene dosage and altered expression of 
many genes simultaneously, some of which could 
promote oncogenesis while others could perform 
inhibitory roles. The oncogenic mechanisms 
underlying remain largely elusive and it is unclear if 
gain of X chromosome directly contributes to 
malignant transformation or aneuploidy-induced 
transcriptional changes might only allow direct 
acquisition of cancer-driving mutations. 
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